JP2017501137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501137A5 JP2017501137A5 JP2016535646A JP2016535646A JP2017501137A5 JP 2017501137 A5 JP2017501137 A5 JP 2017501137A5 JP 2016535646 A JP2016535646 A JP 2016535646A JP 2016535646 A JP2016535646 A JP 2016535646A JP 2017501137 A5 JP2017501137 A5 JP 2017501137A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- biomarker
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910663P | 2013-12-02 | 2013-12-02 | |
| US61/910,663 | 2013-12-02 | ||
| US201461975339P | 2014-04-04 | 2014-04-04 | |
| US61/975,339 | 2014-04-04 | ||
| PCT/US2014/068097 WO2015084808A1 (en) | 2013-12-02 | 2014-12-02 | Identification of predictive biomarkers associated with wnt pathway inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017501137A JP2017501137A (ja) | 2017-01-12 |
| JP2017501137A5 true JP2017501137A5 (enExample) | 2018-01-18 |
Family
ID=53274023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535646A Pending JP2017501137A (ja) | 2013-12-02 | 2014-12-02 | Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3077546A4 (enExample) |
| JP (1) | JP2017501137A (enExample) |
| CN (1) | CN105829547A (enExample) |
| AU (1) | AU2014357354A1 (enExample) |
| CA (1) | CA2931975A1 (enExample) |
| HK (1) | HK1223657A1 (enExample) |
| MX (1) | MX2016007066A (enExample) |
| TW (1) | TW201610168A (enExample) |
| WO (1) | WO2015084808A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| WO2017023971A1 (en) * | 2015-08-03 | 2017-02-09 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| RU2018113437A (ru) * | 2015-09-16 | 2019-10-17 | Тобира Терапьютикс, Инк. | Комбинированная терапия с использованием ценикривирока для лечения фиброза |
| CA3041325A1 (en) * | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CN106990245B (zh) * | 2017-04-05 | 2018-07-31 | 东南大学 | 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN110835372B (zh) * | 2019-11-06 | 2020-12-01 | 上海健康医学院 | 一种靶向Frizzled7单克隆抗体及其制备方法与应用 |
| JP7593584B2 (ja) * | 2020-03-10 | 2024-12-03 | 学校法人杏林学園 | 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN115337400A (zh) * | 2021-05-13 | 2022-11-15 | 中国科学院分子细胞科学卓越创新中心 | 诊断和治疗肿瘤的试剂及其用途 |
| CN113293212A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用 |
| JPWO2023113013A1 (enExample) * | 2021-12-17 | 2023-06-22 | ||
| JP2026510457A (ja) * | 2023-03-15 | 2026-04-06 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | がんの層別化及び処置 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO2001002568A2 (en) * | 1999-07-02 | 2001-01-11 | Chiron Corporation | Human genes and gene expression products |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| EP1549144A4 (en) * | 2002-10-04 | 2010-01-06 | Univ California | METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1725585A2 (en) | 2004-03-10 | 2006-11-29 | Lonza Ltd | Method for producing antibodies |
| US20080312425A1 (en) | 2004-08-30 | 2008-12-18 | Lonza Biologics Plc. | Ion Exchange Chromatography and Purification of Antibodies |
| EP1945754B1 (en) | 2005-10-31 | 2014-07-23 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| AR062709A1 (es) | 2006-09-08 | 2008-11-26 | Genentech Inc | Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt |
| HRP20160082T1 (hr) | 2006-09-29 | 2016-02-26 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
| US20100130374A1 (en) * | 2006-09-29 | 2010-05-27 | Annuska Maria Glas | High-throughput diagnostic testing using arrays |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| US8093364B2 (en) | 2008-01-18 | 2012-01-10 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| EP2331136B1 (en) | 2008-09-26 | 2018-01-10 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| US20100169025A1 (en) * | 2008-10-10 | 2010-07-01 | Arthur William T | Methods and gene expression signature for wnt/b-catenin signaling pathway |
| US20120053079A1 (en) * | 2009-03-06 | 2012-03-01 | University Of South Alabama | Methods and compositions for the diagnosis, prognosis and treatment of cancer |
| EP2523974A4 (en) | 2010-01-12 | 2013-11-06 | Oncomed Pharm Inc | WNT BINDER AND APPLICATIONS THEREOF |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
-
2014
- 2014-12-02 EP EP14867583.8A patent/EP3077546A4/en not_active Withdrawn
- 2014-12-02 AU AU2014357354A patent/AU2014357354A1/en not_active Abandoned
- 2014-12-02 WO PCT/US2014/068097 patent/WO2015084808A1/en not_active Ceased
- 2014-12-02 CN CN201480065718.7A patent/CN105829547A/zh active Pending
- 2014-12-02 CA CA2931975A patent/CA2931975A1/en not_active Abandoned
- 2014-12-02 TW TW103141799A patent/TW201610168A/zh unknown
- 2014-12-02 JP JP2016535646A patent/JP2017501137A/ja active Pending
- 2014-12-02 HK HK16111927.7A patent/HK1223657A1/zh unknown
- 2014-12-02 MX MX2016007066A patent/MX2016007066A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| JP2016520289A5 (enExample) | ||
| JP6781184B2 (ja) | がん転移の予後診断および処置のための方法 | |
| Fayette et al. | Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study) | |
| JP2022060489A (ja) | ｃ－ＭＡＦの状態に基づく乳がんの治療的処置 | |
| JP2014524746A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| JP2017517507A5 (enExample) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2008523073A5 (enExample) | ||
| RU2016147398A (ru) | Способы оценивания и лечения острого миелоидного лейкоза | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| WO2014151606A4 (en) | Methods of treating pancreatic cancer | |
| JP2019523641A5 (enExample) | ||
| JP2018525994A5 (enExample) | ||
| RU2015102194A (ru) | Способы лечения связанных с fgfr3 состояний | |
| JP2015530868A5 (enExample) | ||
| JP7481255B2 (ja) | 抗体薬物複合体の感受性マーカー | |
| JP2015210268A5 (enExample) | ||
| JP2017527533A5 (enExample) | ||
| Chua et al. | Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| Aieta et al. | Monitoring and characterization of circulating tumor cells (CTCs) in a patient with EML4-ALK–Positive Non–Small cell lung cancer (NSCLC) | |
| JP2016514130A5 (enExample) | ||
| JP7298827B2 (ja) | 抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法 |